Tag - Samsung Bioepis likely to delay Nasdaq debut

Samsung Bioepis likely to delay Nasdaq debut

Samsung Group’s biosimilars unit is likely to delay its public listing on the Nasdaq, originally scheduled for the first half of this year, industry sources said Tuesday. Samsung Bioepis, which develops biosimilars — cheaper near-replicas of brand-name biologic drugs — had sought to raise up to 2 trillion won ($1.7 billion) through the initial public offering to pour more resources into research and development activities. According to news reports and sources, however, the company is unlikely to pursue its debut on [...]

Read more...